



HAL
open science

Gender does not impact the short- or long-term outcomes of home-based pulmonary rehabilitation in patients with COPD

Jean-Marie Grosbois, Sarah Gephine, Anne Sophie Diot, Maeva Kyheng, François Machuron, Gaelle Terce, Benoit Wallaert, Cécile Chenivesse, Olivier Le Rouzic

► To cite this version:

Jean-Marie Grosbois, Sarah Gephine, Anne Sophie Diot, Maeva Kyheng, François Machuron, et al.. Gender does not impact the short- or long-term outcomes of home-based pulmonary rehabilitation in patients with COPD. ERJ Open Research, 2020, ERJ Open Research, 6 (4), pp.00032-2020. 10.1183/23120541.00032-2020 . hal-03019306v1

HAL Id: hal-03019306

<https://hal.univ-lille.fr/hal-03019306v1>

Submitted on 23 Nov 2020 (v1), last revised 31 May 2021 (v2)

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.



L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License



Gender does not impact the short- or long-term outcomes of home-based pulmonary rehabilitation in patients with COPD

Jean-Marie Grosbois^{1,2}, Sarah Gephine^{3,4}, Anne Sophie Diot⁵, Maeva Kyheng^{6,7}, François Machuron^{6,7}, Gaëlle Terce², Benoit Wallaert ^{5,8,9}, Cécile Chenivresse^{5,8,9} and Olivier Le Rouzic ^{5,8,9}

Affiliations: ¹FormAction Santé, Pérenchies, France. ²CH Béthune, Service de Pneumologie et Réhabilitation Respiratoire, Béthune, France. ³Univ. Lille, Univ. Artois, Univ. Littoral Côte D'opale, ULR 7369-Urepsss- Lille, Lille, France. ⁴Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval, Québec, Canada. ⁵CHU Lille, Service de Pneumologie et Immuno-Allergologie, Centre de Référence Constitutif des Maladies Pulmonaires Rares, Lille, France. ⁶CHU Lille, Department de Biostatistiques, Lille, France. ⁷Univ. Lille, CHU Lille, ULR 2694 - METRICS: évaluation des technologies de santé et des pratiques médicales, Lille, France. ⁸Univ. Lille, Lille, France. ⁹Inserm, CNRS, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Centre for Infection and Immunity of Lille, Lille, France.

Correspondence: Jean-Marie Grosbois, FormAction Santé, ZA du bois rue de Pietralunga, 59840 Pérenchies, France. E-mail: jmgrosbois@formactionsante.com

ABSTRACT Pulmonary rehabilitation, whether performed at home or in a specialised centre, is effective in the management of COPD. As gender-related differences in COPD were previously reported, we aimed to evaluate the impact of gender on pulmonary rehabilitation outcomes in the short, medium and long term.

In this retrospective observational study of 170 women and 310 men with COPD, we compared the outcomes of an 8-week home-based pulmonary rehabilitation programme including an individualised plan of retraining exercises, physical activities, therapeutic education, and psychosocial and self-management support. Exercise tolerance, anxiety, depression, and quality of life (QOL) were assessed using the 6-min stepper test (6MST), Hospital Anxiety and Depression Scale (HADS) and Visual Simplified Respiratory Questionnaire (VSRQ), respectively. Assessments were carried out before, immediately after the pulmonary rehabilitation programme (T2) and at 8 (T8) and 14 months (T14).

At baseline, women were younger (mean 62.1 *versus* 65.3 years), more often nonsmokers (24.7% *versus* 7.7%) and had a higher body mass index (28 *versus* 26.4 kg·m⁻²). They more often lived alone (50.6% *versus* 24.5%) and experienced social deprivation (66.7% *versus* 56.4%). They had significantly lower exercise tolerance (−34 strokes, 6MST) and higher anxiety and depression (+3.2 HADS total score), but there were no between gender differences in QOL (VSRQ). Both groups showed similar improvements in all outcome measures at T2, T8 and T14 with a tendency for men to lose QOL profits over time.

Despite some differences in baseline characteristics, women and men with COPD had similar short-, medium- and long-term benefits of a home-based pulmonary rehabilitation programme.



@ERSpublications

Despite some differences in baseline characteristics, women and men with COPD had similar short-, medium- and long-term benefits of a home-based pulmonary rehabilitation programme
<https://bit.ly/2XfFakK>

Cite this article as: Grosbois J-M, Gephine S, Diot AS, *et al.* Gender does not impact the short- or long-term outcomes of home-based pulmonary rehabilitation in patients with COPD. *ERJ Open Res* 2020; 6: 00032-2020 [https://doi.org/10.1183/23120541.00032-2020].



Introduction

The prevalence of chronic obstructive pulmonary disease (COPD) among women is steadily increasing due in large part to more frequent occupational exposure to noxious particles and increased smoking among women since the 1960s [1]. Habits have changed, and women also find it more difficult than men to quit smoking and to remain nonsmokers [1, 2]. Despite the increasing prevalence, the diagnosis of COPD is often delayed in women, who report higher difficulties in meeting a specialist and feel the time of consultation to be insufficient compared with male patients [3]. With similar smoking habits, women with COPD generally have a more severe disease, experience worse dyspnoea and quality of life (QOL) and have a higher risk of hospitalisation [2]. Taken together, COPD-related factors could hamper the attendance to pulmonary rehabilitation and its benefits. As a result, whereas mortality from COPD has declined among men since the early 2000s, it has remained stable among women [4]. Hence, there is an urgent need to improve screening and treatment strategies for women with COPD.

Pulmonary rehabilitation is a comprehensive patient-focused treatment that combines retraining exercises, physical activities, therapeutic education and self-management support [5]. In COPD, it has demonstrated effectiveness in improving exercise tolerance, dyspnoea, QOL, anxiety and depression, and in reducing exacerbation frequency, the duration of hospitalisations and COPD-related health costs [5, 6]. We and others have shown that home-based pulmonary rehabilitation programmes are effective in improving exercise tolerance, dyspnoea and QOL in patients with COPD [7, 8].

Gender, as opposed to the term sex, commonly used to refer to the biological characteristics that define men and women, refers to the socially and culturally constructed roles, behaviours and attributes that a given society considers appropriate for men and women. Although gender is considered as a determinant of health in the same way as age, socioeconomic level, culture and ethnicity [9], only a few studies have investigated the impact of being a woman defined by the term gender in pulmonary rehabilitation outcomes. A systematic review on this subject concluded that studies showed insufficient evidence and conflicting results across studies [10]. Recently, SPIELMANN *et al.* [11] found no difference between genders in exercise tolerance improvement after pulmonary rehabilitation. NGUYEN *et al.* [12] confirmed the previous short-term results but mentioned that QOL was improved only in women. To our knowledge, no study has evaluated the impact of gender on long-term outcomes in a home-based setting.

The aim of our study was to determine whether gender influenced the outcomes of a home-based pulmonary rehabilitation programme in COPD patients over the short-, medium- and long-term.

Methods

Patients

In a retrospective study, we analysed data from all consecutive COPD patients undergoing a home-based pulmonary rehabilitation programme between January 2010 and July 2017 provided by FormAction Santé, Northern France. The study population included 480 patients (figure 1) referred by their pulmonologist for a home-based pulmonary rehabilitation programme because of disabling dyspnoea despite optimal treatment. Patients decided to participate in a centre- or home-based pulmonary rehabilitation programme according to personal preference and/or unavailability of a pulmonary rehabilitation centre close to the patient's home. Exclusion criteria included the occurrence of exacerbation in the preceding 4 weeks, lung cancer, dementia, uncontrolled psychiatric illness or any serious condition (cardiovascular, neurological, osteoarticular, etc.) that could prevent physical activity or be exacerbated by exercise. The prescribing physician was responsible for the diagnosis and assessment of COPD and comorbidities, treatments (other than pulmonary rehabilitation), validation of the absence of contraindications to exercise and determination of the retraining target heart rate. Social deprivation was assessed using the Evaluation of Deprivation and Inequalities in Health Centres (EPICES) multidimensional questionnaire [13], which evaluates social deprivation on a quantitative and continuous scale ranging from 0 (no deprivation) to 100 (maximum deprivation). Forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV₁) were measured at baseline by spirometry.

This study was conducted in accordance with the principles described in the amended Declaration of Helsinki and approved by the Committee for the Evaluation of Observational Research Protocols of the French Language Pulmonary Society (CEPRO 2017-007). All patients provided written informed consent for the use of the data.

Pulmonary rehabilitation programme

The home-based pulmonary rehabilitation programme has been described previously in detail [8, 14]. Briefly, it consisted of a 1.5-hour in-home session per week, supervised by a member of the pulmonary rehabilitation team, for 8 weeks, with unsupervised exercises during the other days of the week, and one visit 6 and 12 months after the end of pulmonary rehabilitation. The pulmonary rehabilitation programme




FIGURE 1 Flow chart.

started with an evaluation of the patient's needs and expectations leading to the formulation of a personalised plan. Educational, motivational and self-management plans were designed and implemented through a collaborative process between the pulmonary rehabilitation team, the patient and his/her caregiver [15]. Follow-up visits were restricted to the planned assessments; otherwise, patients were followed by health professionals according to their usual schedule of care.

Endurance exercises were performed on a cycle ergometer or a stepper at the target heart rate, with the goal of working up to 30 to 45 min daily [8]. For very severe COPD patients, exercise training was started with a duration of a few minutes repeated several times a day, with the goal of reaching 10 min at a time and 30 to 45 min per day. If necessary, an oxygen supply was delivered. Patients managed their exercise intensity based on dyspnoea (target of 3–4 on a Borg 1–10 scale) or perception of effort (target of 11–13 on a Borg 6–20 scale). Strengthening exercises with dumbbells and/or elastibands were offered, to be performed in 10-min sessions for 5 days a week, depending on the patient's abilities and motivations, as well as balance exercises.

The programme was focused on the resumption of daily activities (e.g., walking, cleaning, gardening and shopping) according to the patient's wishes and environment, with the goal of facilitating long-term integration of the programme into the patient's lifestyle and circumstances.

Assessments

Assessments were performed at home at baseline, at the end of the 8-week pulmonary rehabilitation programme (T2), and at 8 (T8) and 14 months (T14) after baseline. Exercise tolerance was assessed by the 6-min stepper test (6MST) [16], anxiety and depression by the Hospital Anxiety and Depression Scale (HADS) [17] and QOL by the Visual Simplified Respiratory Questionnaire (VSRQ) [18]. The minimally clinically important differences (MCIDs) were 40 strokes for the 6MST [19], 1.5 points for HADS-Anxiety,

1.5 points for HADS-Depression [17] and 3.4 points for VSRQ [18]. Patients were considered “responders” if their test scores improved by at least the MCID between T0 and T2, T8, or T14.

Statistical analysis

Patients were classified according to their biological sex. Quantitative variables are presented as mean and SD or median and interquartile range according to the normality of distribution, as determined graphically and by the Shapiro–Wilk test. Qualitative variables are presented as frequencies and percentages. Categorical variables were compared using Chi-squared tests. Quantitative variables were compared using Student’s parametric tests when normally distributed, otherwise using nonparametric Wilcoxon tests. Baseline variables (6MST, VSRQ HADS-Anxiety and HADS-Depression) and all changes from baseline (T0) to T2, T8 or T14 were compared between men and women using covariance analysis (ANCOVA).

Global progressions of parameters were compared between the two patient groups (women *versus* men) using linear mixed models by adjusting the value to baseline. Quality of the linear models was verified by analysis of residuals. In the case of non-normality of residuals, the data were log-transformed. All analyses (ANOVA and linear mixed models) were adjusted for confounding factors (age, body mass index (BMI), living arrangement, smoking status, FEV₁ percentage of predicted, EPICES and coronary artery disease or peripheral vascular disease). The significance threshold was set at 0.05. All analyses were performed using SAS software version 9.4 (SAS Institute, Cary, NC, USA).

Results

The study population was composed of 480 patients (mean age 64.2 years) with severe COPD (mean FEV₁ 36% pred), including 170 women (35.4%) (table 1). Compared with men, women were significantly younger and had significantly higher BMI and FVC, whereas FEV₁ and Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages distribution were similar between genders. Women more often lived alone, were non-smokers and presented with social deprivation. Women were also less likely to have

TABLE 1 Baseline characteristics

Parameter	All patients	Women	Men	p-value
Subjects n	480	170	310	
Age years	64.2±11.3	62.1±12.3	65.3±10.6	0.004
BMI kg·m⁻²	27.0±7.7	28.0±9.1	26.4±6.8	0.045
Living arrangement				<0.001
Alone	162 (33.7)	86 (50.6)	76 (24.5)	
Smoking status				<0.001
Smoker	84 (17.5)	33 (19.4)	51 (16.5)	
Nonsmoker	66 (13.7)	42 (24.7)	24 (7.7)	
Ex-smoker	330 (68.8)	95 (55.9)	235 (75.8)	
Pack-years	45 (30, 65)	40 (24, 60)	45 (34, 70)	<0.001
Pulmonary function tests				
FEV ₁ % pred	36.0 (26, 48)	37.0 (28, 48)	35.0 (25, 45)	0.088
FVC % pred	61.0 (49.5, 75)	64.0 (52, 80)	60.0 (48, 73)	0.018
GOLD stages				0.26
1	4 (1.0)	2 (1.4)	2 (0.8)	
2	81 (19.7)	29 (19.7)	52 (19.7)	
3	186 (45.3)	73 (49.7)	113 (42.8)	
4	140 (34.1)	43 (29.3)	97 (36.7)	
LTOT	319 (66.5)	110 (64.7)	209 (67.4)	0.55
NIV	163 (34.0)	55 (32.4)	108 (34.8)	0.58
CPAP	41 (8.5)	11 (6.5)	30 (9.7)	0.23
EPICES score/100	38.5±18.8	41.6±20.3	36.7±17.7	0.011
Classified as socioeconomically deprived	288 (60)	113 (66.5)	175 (56.4)	0.031
Presence of coronary artery disease or peripheral vascular disease	127 (26.5)	27 (15.9)	100 (32.3)	<0.001

Categorical data are presented as n (%). Continuous variables are presented as mean±SD or median (Q1, Q3) depending on the normality of data distribution. BMI: body mass index; FEV₁: forced expiratory volume in 1 s; FVC: forced vital capacity; GOLD: Global Initiative for Chronic Obstructive Lung Disease; NIV: noninvasive ventilation; LTOT: long-term oxygen therapy; CPAP: continuous positive airway pressure; EPICES: Evaluation of Deprivation and Inequalities in Health Centres (0 to 100 scale, minimum to maximum social deprivation). Bold type indicates p<0.05.

coronary artery or peripheral vascular diseases, or sleep apnoea syndrome than men (15.9% versus 32.3%, $p<0.001$; 14.1% versus 22.2%, $p=0.03$, respectively). While diagnosed anxiety, depression, dysthyroidism and osteoporosis were significantly more common in women (40.2% versus 29.8%, $p<0.001$; 30.5% versus 19.4%, $p<0.01$; 19.4% versus 3.5%, $p<0.001$; 12.3% versus 4.5%, $p=0.002$; respectively), asthma and chronic heart failure prevalence were not different between genders.

The percentage of men and women evaluated at the different steps of the study did not differ significantly (89.4% versus 91.9% at T2, 80% versus 79.7% at T8 and 71.8% versus 69.7% at T14) neither did the withdrawal reasons or number of deaths ($p=0.12$) (figure 1). No incidents or accidents related to the pulmonary rehabilitation programme were reported. Compared with patients who completed the study, those who dropped out during the 14-month study for any reason ($n=140$, 29.2%) including death, presented with a more severe disease at baseline (FEV_1 33.5% versus 41%, $p<0.001$), more often received long-term oxygen therapy (LTOT) (80% versus 60.9%, $p<0.001$) and/or noninvasive ventilation (41.4% versus 30.9%, $p=0.027$), and were more often affected by coronary artery or peripheral vascular diseases (36.4% versus 22.4%, $p<0.001$). Death occurred in 42 patients (8.7%) who were older (69.1 versus 63.7 years, $p<0.001$), had lower exercise tolerance (6MST 230.8 versus 315.2 strokes, $p<0.001$), received LTOT more frequently (85.7% versus 64.6%, $p=0.006$), and more often suffered from heart failure (26.2% versus 10%, $p=0.004$) and rhythm disorders (31% versus 16.4%, $p=0.019$) compared with the survivors.

At baseline, women had significantly higher total HADS and HADS-Anxiety scores as well as HADS-Depression scores after adjustment for confounding factors and completed significantly fewer strokes in the 6MST compared with men (table 2). VSRQ score was not statistically different between groups.

Men and women showed similar improvements in outcomes measured at 2, 8 and 14 months after the start of the pulmonary rehabilitation programme (figure 2 and table 3). After adjustment to confounders, there was no impact of gender on the magnitude of improvement in 6MST strokes and HADS scores (total, anxiety and depression). The improvement in the VSRQ score was significantly higher in women than men between T0 and T2 only after adjustment and this difference was also found at T14 with or without adjustment. The percentage of men and women who met the definition of a pulmonary rehabilitation responder (\geq MCID change from baseline in at least one of the four outcome measures) tended to decrease over time but was not significantly different between men and women at T2, T8 or T14 (table 4). With respect to individual outcomes, the percentage of patients with \geq MCID change in HADS-Anxiety subscore differed significantly only at T8 (37% women versus 50% men, $p=0.02$) (figure 3). In contrast, a greater proportion of women showed \geq MCID improvement in the VSRQ score at T14 (64.6% versus 52.1%, $p=0.04$).

Discussion

The results of this retrospective observational study identified no gender-based differences in the outcomes of a home-based pulmonary rehabilitation programme in COPD patients. In our study, women entering a home-based pulmonary rehabilitation programme in comparison with men were younger, had a higher BMI, and were less likely to be smokers or to present with coronary artery or peripheral vascular diseases. They more often lived alone, had a higher level of social deprivation, and had greater levels of anxiety,

TABLE 2 Assessments at baseline

Parameter	All patients	Women	Men	p-value	Adjusted p-value [#]
Subjects n	480	170	310		
HADS score					
Total	17.8±7.7	19.9±8.1	16.7±7.3	<0.001	<0.001
Anxiety subscore	9.9±4.6	11.5±4.6	8.9±4.3	<0.001	<0.001
Depression subscore	8.0±4.2	8.4±4.6	7.8±4.0	0.14	0.044
VSRQ score	31.2±15.3	29.3±14.6	32.0±15.7	0.089	0.074
6MST strokes	310.1±154.0	288.5±148.2	321.7±156	0.038	<0.001

Data are presented as mean±sd, unless otherwise stated. HADS: Hospital Anxiety Depression Scale [0–21 subscores, low to high anxiety/depression; 0–42 total score]; VSRQ: Visual Simplified Respiratory Questionnaire [0–80, low to high quality of life]; 6MST: number of strokes in the 6-min stepper test.
[#]: Adjusted for age, body mass index, living arrangement, smoking status, forced expiratory volume in 1 s (FEV_1) [% pred], Evaluation of Deprivation and Inequalities in Health Centres (EPICES), and coronary artery disease or peripheral vascular disease. Bold type indicates $p<0.05$.




FIGURE 2 Changes in exercise tolerance, quality of life, anxiety and depression in COPD patients according to gender. (a–d) Changes in parameters from T0 (baseline) to T2, T8 and T14 (2, 8 and 14 months after T0) for (a) Hospital Anxiety and Depression Scale (HADS) anxiety subscore, (b) HADS-depression subscore, (c) 6-min stepper test (6MST) stroke number and (d) Visual Simplified Respiratory Questionnaire (VSRQ) score. Data are presented as the mean \pm SEM at each time for the whole population. p-values are adjusted for baseline value of age, body mass index, living arrangement, smoking status, forced expiratory volume in 1 s (FEV₁) (% pred), EPICES (Evaluation of Deprivation and Inequalities in Health Centres) score, and coronary artery disease or peripheral vascular disease. p-value is the $P_{\text{interaction}}$ for the interaction between time and group (i.e. <0.05 indicates a significant difference in the change in variable with time compared between the two patient groups). All analyses were adjusted to the baseline value. Minimum–maximum scores: HADS total, 0–42; HADS subscores, 0–21 (low to high anxiety/depression); VSRQ, 0–80 (low to high quality of life).

depression and exercise intolerance. Nevertheless, women and men showed similar beneficial effects of pulmonary rehabilitation on depression, anxiety, QOL and exercise tolerance, and they were similarly able to sustain these benefits for up to 1 year thereafter with a tendency for men to lose QOL profits over time.

Epidemiological characteristics of our study population are consistent with previous studies of COPD patients, in that the women were younger and less often smokers than men with the same degree of airflow limitation [2]. An audit of several outpatient pulmonary rehabilitation programmes in the UK found that COPD patients with lower socioeconomic status were less likely to adhere to the programme, but those who did complete the programme had similar outcomes to patients with higher socioeconomic status [20]. In our study, although the women were more socially deprived than the men, they showed similar attendance to the home-based pulmonary rehabilitation programme, suggesting that this modality could better meet their needs and overcome their socioeconomic limitations compared with outpatient or inpatient pulmonary rehabilitation programmes. This is an important finding because non-attendance and premature cessation are common during pulmonary rehabilitation programmes. Identified predictors of pulmonary rehabilitation non-attendance are socioeconomic disadvantage, advanced age, active smoking, severe obstruction, LTOT use, low QOL and distance from a pulmonary rehabilitation site [21]. Our results suggest that gender does not affect the long-term attendance to home-based pulmonary rehabilitation. Home-based programmes have considerable advantages for patients who are otherwise unable to visit a pulmonary rehabilitation centre by allowing them to benefit from a personalised pulmonary rehabilitation programme that takes into account constraints in their daily activities and living environment.

In the present study, women with COPD had higher baseline anxiety and depression scores than men, which is consistent with a report that anxio-depressive disorders were twice as common in women than men with COPD (56% versus 35% with anxiety symptoms, 38% versus 13% with depression symptoms), despite there being no difference in COPD severity [22]. Anxiety disorders are known to alter therapeutic

TABLE 3 Changes in outcome measures in women and men with chronic obstructive pulmonary disease (COPD) at 2, 8 and 14 months after initiation of pulmonary rehabilitation

	Women		Men		p-value	Adjusted p-value [#]
	n	mean	n	mean		
HADS total score						
Score at T0	168	19.9±8.1	306	16.7±7.32	<0.001	<0.001
Change from T0 to T2	150	-3.8±6.5	280	-2.7±6.0	0.062	0.14
Change from T0 to T8	127	-5.1±7.3	238	-3.7±6.0	0.064	0.54
Change from T0 to T14	117	-5.0±7.4	213	-3.5±6.0	0.054	0.24
HADS-Anxiety subscore						
Subscore at T0	167	11.5±4.6	298	8.9±4.3	<0.001	<0.001
Change from T0 to T2	150	-1.8±3.8	280	-1.1±3.4	0.044	0.20
Change from T0 to T8	127	-2.7±4.3	238	-1.5±3.9	0.009	0.13
Change from T0 to T14	118	-2.3±4.5	213	-1.7±3.6	0.23	0.59
HADS-Depression subscore						
Subscore at T0	167	8.4±4.6	298	7.8±4.0	0.14	0.044
Change from T0 to T2	150	-2.1±3.7	280	-1.6±3.6	0.23	0.38
Change from T0 to T8	127	-2.4±4.2	238	-2.2±3.3	0.60	0.60
Change from T0 to T14	118	-2.7±4.2	213	-1.8±3.8	0.054	0.18
VSRQ score						
Score at T0	140	29.3±14.6	271	32.0±15.7	0.089	0.074
Change from T0 to T2	128	+8.5±14.1	251	+7.8±13.4	0.66	0.049
Change from T0 to T8	107	+9.2±13.7	215	+7.5±14.3	0.29	0.55
Change from T0 to T14	96	+9.5±14.7	194	+5.7±14.3	0.035	0.036
6MST strokes						
Score at T0	136	288.5±148.2	251	321.7±156	0.038	<0.001
Change from T0 to T2	122	+65.4±97.0	219	+59.2±100.7	0.58	0.32
Change from T0 to T8	94	+37.4±119.3	152	+43.7±128.2	0.70	0.19
Change from T0 to T14	73	+46.2±102.0	120	+61.8±134.3	0.40	0.093

Baseline mean values (T0), and change from T0 to 2 (T2), 8 (T8) and 14 (T14) months. Changes at each time are only calculated in patients for whom data were available at the time considered and at T0. Results are expressed as the mean±sd. HADS: Hospital Anxiety Depression Scale; VSRQ: Visual Simplified Respiratory Questionnaire; 6MST: number of strokes in the 6-min stepper test. #: p-value adjusted for age, body mass index, living arrangement, smoking status, forced expiratory volume in 1 s (FEV₁) (% pred), Evaluation of Deprivation and Inequalities in Health Centres (EPICES) score, and coronary artery disease or arteritis. Bold type indicates p<0.05.

observance [23] and attendance to pulmonary rehabilitation programmes[24], making it reasonable to assume that they may also impact pulmonary rehabilitation outcomes. There is a paucity of data on how gender affects the benefits of pulmonary rehabilitation on psychological outcomes. HAASVE *et al.* [25] reported that men and women with COPD showed similar improvements in the trait portion of the Spielberger State-Trait Anxiety Inventory after pulmonary rehabilitation, whereas NGUYEN *et al.* [12] found that women had more marked improvements than men in depression based on the Patient Health

TABLE 4 Percentage of pulmonary rehabilitation responders according to gender

Time point	Responders in at least one parameter		p-value
	Women	Men	
Subjects n	170	310	
T2	141 (82.9)	269 (86.8)	0.26
T8	115 (67.6)	221 (71.3)	0.40
T14	110 (64.7)	193 (62.3)	0.59

Data are presented as n (%) pulmonary rehabilitation responders, defined as ≥MCID change from baseline to 2, 8 and 14 months in at least one of the four tests: 6-min stepper test, Hospital Anxiety and Depression Scale (subscores) or Visual Simplified Respiratory Questionnaire. MCID: minimum clinically important difference.




FIGURE 3 Percentage of patients who responded to pulmonary rehabilitation according to gender. Data are presented as the percentage of patients who responded to pulmonary rehabilitation, with response defined as a change of \geq MCID for the indicated assessments at 2 (T2), 8 (T8) and 14 (T14) months compared with the start of the pulmonary rehabilitation programme. 6MST: number of strokes in the 6-min stepper test; MCID: minimum clinically important difference; VSRQ: Visual Simplified Respiratory Questionnaire. *: $p < 0.05$.

Questionnaire-9, and neither group showed improvement in anxiety based on the Generalised Anxiety Disorder-7 score. In contrast, in the present study, we found significant and comparable improvements in HADS-Anxiety and HADS-Depression scores in both men and women in the short, medium and long term after pulmonary rehabilitation, suggesting that the choice of evaluation tools may be responsible for discrepancies between studies.

Consistent with some previous reports, we found that QOL at baseline was not significantly different between women and men with COPD [26, 27]. However, other studies have reported lower global QOL scores in women with COPD [28, 29] or found significant gender differences in specific components of QOL evaluation [30, 31]. The discrepancies between these studies may reflect the difficulty of examining gender differences with such a broad outcome measure as QOL, which may be affected by numerous other factors, such as deterioration of exercise tolerance, changes in stress and comorbidities. In our study, QOL improvement at the end of pulmonary rehabilitation was statistically but not clinically higher in women after adjustment for confounders. Our results are in accordance with most studies in this area, which have found no effect of gender on improvement in QOL after pulmonary rehabilitation, independently of the evaluation tool used [11, 25, 32–36]. Only two studies to date have reported a gender difference in QOL in COPD patients; one found that women benefited more from pulmonary rehabilitation than men [12, 37] and the second found the reverse [38]. In our population, a higher percentage of women showed a clinically significant improvement in the long term. This is mainly due to the gradual decline in the percentage of male responders while the proportion of female responders remained stable. This finding suggests that there may be a gender difference in COPD patient ability to maintain the beneficial effects of pulmonary rehabilitation on QOL over the long term. This is an important observation because, to our knowledge, only two other studies of COPD patients [26, 27] have compared gender differences in QOL at 6 months after pulmonary rehabilitation, and no studies have investigated such differences at 12 months after pulmonary rehabilitation.

In our study population, women with COPD had lower exercise tolerance than men with the same degree of airflow limitation as reported by other groups [11, 32, 39]. No gender differences have been reported in the short-term benefits of pulmonary rehabilitation on exercise tolerance in COPD patients [11, 12, 25, 33, 35–37, 40], with the exception of Skumlien *et al.* [38] who reported greater improvement in men. Our study additionally found no gender-based differences in exercise tolerance over the medium and long term after pulmonary rehabilitation. This durability of improvement may be due, at least in part, to the integration of patient-selected physical activities of daily living from the start of the pulmonary rehabilitation programme.

Our study is limited by its retrospective and observational design. A recruitment bias was possible, because selection of home-based pulmonary rehabilitation was based on patient's personal choice and/or geographical distance from a rehabilitation centre and some patients were lost to follow-up before the long-term reassessment. However, this possible recruitment bias should be the same between men and

women. We can even suggest that because of specific social roles attributed to women by the society, a home-based programme could facilitate the attendance and adherence in women, compared to traditional settings. Moreover, as previously reported, this modality of pulmonary rehabilitation is as effective as programmes taking place in rehabilitation facilities with good attendance rates and provides an innovative solution to better meet the patient's needs. Finally, our classification criterion being biological sex, patients who identify themselves as belonging to a gender different to their biological sex could have been misclassified. As sex is a main determinant of gender and identity construction, this should only concern a few patients. Furthermore, gender seems more appropriate to describe our groups as pulmonary rehabilitation responses seem more determined by the individual as a whole and not only dictated by sex-related biological characteristics.

In conclusion, this study shows that despite being younger, more socially deprived, more anxious and having a reduced exercise tolerance compared with men, women with COPD showed similar benefits from home-based pulmonary rehabilitation on exercise tolerance, anxiety and depression on a short-, medium- and long-term basis. QOL is more improved in women with a tendency for men to lose profits over time.

Acknowledgements: We thank members of the rehabilitation team at FormAction Santé: Sophie Duriez, Mathieu Grosbois, Marjorie Lambinet, Valentine Opsomer, Gaele Tywoniuk, Florence Urbain and Virginie Wauquier. The authors also wish to thank Anne M. O'Rourke for editing a version of the manuscript.

Author contributions: J-M. Grosbois, B. Wallaert, F. Machuron and A.S. Diot had full access to all data, and take responsibility for the integrity of the data and the accuracy of data analysis, including and especially any adverse effects. J-M. Grosbois, O. Le Rouzic, C. Chenivresse, B. Wallaert, S. Gephine, M. Kyheng and G. Terce contributed substantially to the study design, data analysis and interpretation, and writing of the manuscript.

Conflict of interest: J-M. Grosbois reports FormAction Santé (J-M. Grosbois) received financial support from Adair, Aeris Santé, Bastide, France Oxygène, Homeperf, LVL Medical, Medopale, NorOx, Santély, Santeo, SOS Oxygène, Sysmed, VitalAire and the ARS Hauts de France for the home-based pulmonary rehabilitation programme; personal fees and nonfinancial support from AstraZeneca and Boehringer Ingelheim, personal fees from Chiesi, nonfinancial support from GlaxoSmithKline and Novartis, and personal fees from Vitalaire and Roche, during the conduct of the study. S. Gephine has nothing to disclose. A.S. Diot has nothing to disclose. M. Kyheng has nothing to disclose. F. Machuron has nothing to disclose. G. Terce has nothing to disclose. B. Wallaert reports personal fees and nonfinancial support from Roche and Boehringer Ingelheim, and nonfinancial support from Vitalaire, outside the submitted work. C. Chenivresse reports grants from AstraZeneca and Santély, personal fees from ALK-Abello, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Roche, Sanofi and TEVA, and nonfinancial support from ALK-Abello, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, MEDA Pharma, Medexact, Novartis, Pierre Fabre and Pfizer, outside the submitted work. O. Le Rouzic reports personal fees and nonfinancial support from AstraZeneca, Boehringer Ingelheim, Chiesi, Lilly and Novartis, and nonfinancial support from GlaxoSmithKline, MundiPharma, Pfizer, Teva, Santelys Association, Vertex and Vitalaire, outside the submitted work.

References

- 1 Aryal S, Diaz-Guzman E, Mannino DM. Influence of sex on chronic obstructive pulmonary disease risk and treatment outcomes. *Int J Chron Obstruct Pulmon Dis* 2014; 9: 1145–1154.
- 2 Gut-Gobert C, Cavaillès A, Dixmier A, et al. Women and COPD: do we need more evidence? *Eur Respir Rev* 2019; 28: 180055.
- 3 Martinez CH, Raparla S, Plauschinat CA, et al. Gender differences in symptoms and care delivery for chronic obstructive pulmonary disease. *J Womens Health* 2012; 21: 1267–1274.
- 4 Ni H, Xu J. COPD-related mortality by sex and race among adults aged 25 and over: United States, 2000–2014. *NCHS Data Brief* 2016; 256: 1–8.
- 5 Spruit MA, Singh SJ, Garvey C, et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. *Am J Respir Crit Care Med* 2013; 188: e13–e64.
- 6 McCarthy B, Casey D, Devane D, et al. Pulmonary rehabilitation for chronic obstructive pulmonary disease. *Cochrane Database Syst Rev* 2015; 2: CD003793.
- 7 Holland AE, Mahal A, Hill CJ, et al. Home-based rehabilitation for COPD using minimal resources: a randomised, controlled equivalence trial. *Thorax* 2017; 72: 57–65.
- 8 Grosbois JM, Gicquello A, Langlois C, et al. Long-term evaluation of home-based pulmonary rehabilitation in patients with COPD. *Int J Chron Obstruct Pulmon Dis* 2015; 10: 2037–2044.
- 9 World Health Organization. Women, ageing and health: a framework for action. Focus on gender. 2007. www.who.int/gender-equity-rights/knowledge/9789241563529/en/ Date last accessed: 30 October 2019. Date last updated: 29 October 2019.
- 10 Robles PG, Brooks D, Goldstein R, et al. Gender-associated differences in pulmonary rehabilitation outcomes in people with chronic obstructive pulmonary disease: a systematic review. *J Cardiopulm Rehabil Prev* 2014; 34: 87–97.
- 11 Spielmanns M, Gloeckl R, Schmoor C, et al. Effects on pulmonary rehabilitation in patients with COPD or ILD: a retrospective analysis of clinical and functional predictors with particular emphasis on gender. *Respir Med* 2016; 113: 8–14.
- 12 Nguyen L-P, Beck E, Cayetano K, et al. Differential pulmonary rehabilitation outcomes in patients with and without COPD: role of gender. *J Cardiopulm Rehabil Prev* 2017; 37: 350–355.
- 13 Sass C, Guéguen R, Moulin JJ, et al. [Comparison of the individual deprivation index of the French Health Examination Centres and the administrative definition of deprivation]. *Sante Publique* 2006; 18: 513–522.

- 14 Grosbois J-M, Heluain-Robiquet J, Machuron F, *et al.* Influence of socioeconomic deprivation on short- and long-term outcomes of home-based pulmonary rehabilitation in patients with chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis* 2019; 14: 2441–2449.
- 15 Effing TW, Vercoulen JH, Bourbeau J, *et al.* Definition of a COPD self-management intervention: International Expert Group consensus. *Eur Respir J* 2016; 48: 46–54.
- 16 Grosbois JM, Riquier C, Chehere B, *et al.* Six-minute stepper test: a valid clinical exercise tolerance test for COPD patients. *Int J Chron Obstruct Pulmon Dis* 2016; 11: 657–663.
- 17 Puhan MA, Frey M, Büchi S, *et al.* The minimal important difference of the hospital anxiety and depression scale in patients with chronic obstructive pulmonary disease. *Health Qual Life Outcomes* 2008; 6: 46.
- 18 Perez T, Arnould B, Grosbois J-M, *et al.* Validity, reliability, and responsiveness of a new short Visual Simplified Respiratory Questionnaire (VSRQ) for health-related quality of life assessment in chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis* 2009; 4: 9–18.
- 19 Pichon R, Couturaud F, Mialon P, *et al.* Responsiveness and minimally important difference of the 6-minute stepper test in patients with chronic obstructive pulmonary disease. *Respir Int Rev Thorac Dis* 2016; 91: 367–373.
- 20 Steiner MC, Lowe D, Beckford K, *et al.* Socioeconomic deprivation and the outcome of pulmonary rehabilitation in England and Wales. *Thorax* 2017; 72: 530–537.
- 21 Oates GR, Hamby BW, Stepanikova I, *et al.* Social determinants of adherence to pulmonary rehabilitation for chronic obstructive pulmonary disease. *COPD* 2017; 14: 610–617.
- 22 Laurin C, Lavoie KL, Bacon SL, *et al.* Sex differences in the prevalence of psychiatric disorders and psychological distress in patients with COPD. *Chest* 2007; 132: 148–155.
- 23 DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. *Arch Intern Med* 2000; 160: 2101–2107.
- 24 Busch AM, Scott-Sheldon LAJ, Pierce J, *et al.* Depressed mood predicts pulmonary rehabilitation completion among women, but not men. *Respir Med* 2014; 108: 1007–1013.
- 25 Haave E, Skumlien S, Hyland ME. Gender considerations in pulmonary rehabilitation. *J Cardiopulm Rehabil Prev* 2008; 28: 215–219.
- 26 Ståhl E, Lindberg A, Jansson S-A, *et al.* Health-related quality of life is related to COPD disease severity. *Health Qual Life Outcomes* 2005; 3: 56.
- 27 Rosińczuk J, Przyszlak M, Uchmanowicz I. Sociodemographic and clinical factors affecting the quality of life of patients with chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis* 2018; 13: 2869–2882.
- 28 Katsura H, Yamada K, Wakabayashi R, *et al.* Gender-associated differences in dyspnoea and health-related quality of life in patients with chronic obstructive pulmonary disease. *Respirology* 2007; 12: 427–432.
- 29 Raheison C, Tillie-Leblond I, Prudhomme A, *et al.* Clinical characteristics and quality of life in women with COPD: an observational study. *BMC Womens Health* 2014; 14: 31.
- 30 Di Marco F, Verga M, Reggente M, *et al.* Anxiety and depression in COPD patients: the roles of gender and disease severity. *Respir Med* 2006; 100: 1767–1774.
- 31 Carrasco-Garrido P, de Miguel-Díez J, Rejas-Gutierrez J, *et al.* Characteristics of chronic obstructive pulmonary disease in Spain from a gender perspective. *BMC Pulm Med* 2009; 9: 2.
- 32 Foy CG, Rejeski WJ, Berry MJ, *et al.* Gender moderates the effects of exercise therapy on health-related quality of life among COPD patients. *Chest* 2001; 119: 70–76.
- 33 von Leupoldt A, Hahn E, Taube K, *et al.* Effects of 3-week outpatient pulmonary rehabilitation on exercise capacity, dyspnea, and quality of life in COPD. *Lung* 2008; 186: 387–391.
- 34 Bratås O, Espnes GA, Rannestad T, *et al.* Pulmonary rehabilitation reduces depression and enhances health-related quality of life in COPD patients – especially in patients with mild or moderate disease. *Chron Respir Dis* 2010; 7: 229–237.
- 35 Laviolette L, Lacasse Y, Doucet M, *et al.* Chronic obstructive pulmonary disease in women. *Can Respir J* 2007; 14: 93–98.
- 36 Verrill D, Barton C, Beasley W, *et al.* The effects of short-term and long-term pulmonary rehabilitation on functional capacity, perceived dyspnea, and quality of life. *Chest* 2005; 128: 673–683.
- 37 Haggerty MC, Stockdale-Woolley R, ZuWallack R. Functional status in pulmonary rehabilitation participants. *J Cardiopulm Rehabil* 1999; 19: 35–42.
- 38 Skumlien S, Skogedal EA, Bjørtuft O, *et al.* Four weeks' intensive rehabilitation generates significant health effects in COPD patients. *Chron Respir Dis* 2007; 4: 5–13.
- 39 de Torres JP, Casanova C, Hernández C, *et al.* Gender and COPD in patients attending a pulmonary clinic. *Chest* 2005; 128: 2012–2016.
- 40 Lizak MK, Singh S, Lubina S, *et al.* Female and male chronic obstructive pulmonary disease patients with severe dyspnea do not profit less from pulmonary rehabilitation. *Pol Arch Med Wewn* 2008; 118: 413–418.